Dynavax Technologies Corporation

Good day, ladies and gentlemen, and welcome to the DynaVax Technologies third quarter 2022 financial results. As a reminder, this conference call is being recorded. At the end of the company's prepared remarks, we will open the call for questions and provide specific instructions at that point. I would now like to turn the call over to Nicole Arndt, Senior Manager, Investor Relations. You may now begin.

Thank you. Good afternoon and welcome to the DynaVax third quarter 2022 financial results and corporate update conference call. In addition to our press release issued today, a supplementary slide presentation that accompanies today's call is available in the events section of our website. Before we begin, I advise you that we will be making forward-looking statements today based on our current expectations and beliefs, including but not limited to, potential market sizes and market share, ACIP impact, market trends, growth perspectives, seasonality, financial guidance and trends, including revenue, profitability, and sufficiency of current capitalization. Timing and results of clinical trials starts in data readouts and potential future uses of CPG 1018 adjuvant. These statements involve risks and uncertainties, and our actual results may differ materially. These results are summarized in today's press release and detailed in the risk factor section of our SEC filings, including today's quarterly report on Form 10-Q. Our forward-looking statements speak as of today, and we undertake no obligation to update such statements. Joining me on the call today are Ryan Spencer, Chief Executive Officer, Don Casal, Senior Vice President of Commercial, Rob Jansen, Senior Medical Officer, and Kelly McDonald, Chief Financial Officer. I will now turn the call over to Ryan.

Thank you, Nicole, and thank you all for joining us today. I'm delighted to have the opportunity to discuss the progress we've made this quarter and to review how far we've come over the last few years. It was just three years ago we made a strategic pivot to focus on building a leading vaccine company by committing to drive value through HEPA-SAP-B commercialization and leveraging our CPG-1018 adjuvant to develop new vaccines. At that time, HEPA-SADB revenue for the full year of 2019 ended up at $35 million. Since then, we have seen significant growth as a result of strong execution from our commercial team. HEPA-SADB generated nearly $38 million in revenue in this third quarter alone, keeping us on track for record HEPA-SADB revenues for the full year of 2022 and providing us confidence in the expected continued revenue growth for the future. Also in 2019, we began to focus on broadening utilization of CPG1018 for the development of new vaccines. Today, in addition to HEPACEPV, CPG1018 is used globally in five COVID-19 vaccine programs, which have generated over $800 million in cumulative revenues for DynaVax through the third quarter of this year. Additionally, CPG1018 is the foundation of our expanding development pipeline.